Type 2 diabetes (T2D) is a risk factor for hepatocellular carcinoma (HCC). However, it is unknown whether T2D duration or additional metabolic comorbidities further contribute to HCC risk. From the Nurses' Health Study (NHS), 120,826 women were enrolled in 1980, and from the Health Professionals Follow-up Study (HPFS), 50,284 men were enrolled in 1986 and followed through 2012. Physician-diagnosed T2D was ascertained at baseline and updated biennially. Cox proportional hazards regression models were used to calculate age-and multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for incident HCC. Over 32 years of follow-up (4,488,410 person-years), we documented 112 cases of HCC (69 women, 43 men). T2D was associated with an increased HCC risk (multivariable HR, 4.59; 95% CI, 2.98-7.07), as was an increasing T2D duration (P trend < 0.001). Compared to nondiabetics, the multivariable HRs for HCC were 2.96 (95% CI, 1.57-5.60) for 0-<2 years; 6.08 (95% CI, 2.96-12.50) for 2-<10 years; and 7.52 (95% CI, 3.88-14.58) for 10 years. Increasing number of metabolic comorbidities (T2D, obesity, hypertension, and dyslipidemia) was associated with increased HCC risk (P trend < 0.001); compared to individuals without metabolic comorbidity, those with four metabolic comorbidities had an 8.1-fold increased HCC risk (95% CI, 2.48-26.7). In T2D, neither insulin use nor oral hypoglycemic use was significantly associated with HCC risk (HR, 2.04 [95% CI, 0.69-6.09] and HR, 1.45 [95% CI, 0.69-3.07], respectively). Conclusion: T2D is independently associated with increased risk for HCC in two prospective cohorts of U.S. men and women. This risk is enhanced with prolonged diabetes duration and with comorbid metabolic conditions, suggesting the importance of insulin resistance in the pathogenesis of HCC. (HEPATOLOGY 2018;67:1797-1806 A n estimated 400 million individuals have diabetes worldwide, among whom 85%-95% have type 2 diabetes (T2D).
A n estimated 400 million individuals have diabetes worldwide, among whom 85%-95% have type 2 diabetes (T2D). (1) In the United States, the incidence of diabetes has tripled since the 1980s, (2) and accumulating epidemiologic evidence shows that T2D is associated with an increased risk for numerous cancers, including colon, kidney, breast, pancreas, and liver. (3) (4) (5) Possible mechanisms of diabetes-related carcinogenesis include inflammatory activation, insulin resistance (IR), hyperinsulinemia, and aberrations in insulin-like growth factor-1 (IGF-1) signaling. (6, 7) With an annual worldwide incidence of 500,000 cases/year, hepatocellular carcinoma (HCC) represents the fifth-most common malignancy and the secondleading cause of cancer-related death. (8) In the United States, 35% of HCC cases are attributable to nonalcoholic fatty liver disease (NAFLD) or metabolic syndrome (MetS), (9) and the burden of disease is projected to continue to increase, in parallel with the epidemics of diabetes and obesity. (10) Despite an accelerating incidence, the prognosis for HCC remains very poor, with an estimated median survival of 11 months, and an overall ratio of mortality to incidence of 0.95. (8) As a result, effective preventive strategies are urgently needed to reduce HCC-related morbidity and mortality.
Recent prospective studies have shown that T2D is an independent risk factor for primary liver cancer incidence and mortality. (11) (12) (13) (14) (15) However, data are limited regarding potential modifiers of HCC risk among those with diabetes. Whereas some studies suggest that risk of HCC is increased in individuals with MetS (16, 17) or a prolonged duration of diabetes, (5, 18, 20) others have not found such associations. (21, 22) Moreover, available studies lack prospective collection of comprehensive lifestyle data with serial assessments over time, which is important to accurately estimate the risk associated with an exposure over a prolonged time. (15) To address this, we prospectively examined the association between T2D, duration of T2D, the influence of co-occurring metabolic conditions, and HCC risk in a pooled analysis of the Nurses' Health Study (NHS) and Health Professionals Follow-up Study (HPFS).
Patients and Methods

STUDY POPULATION
The study designs of the NHS and the HPFS cohorts have been described. (23, 24) Briefly, the NHS was established in 1976 with 121,700 female registered nurses in the United States, aged 30-55 years at baseline; the HPFS was established in 1986 with 51,529 male health professionals, aged 40-75 years at baseline. In both cohorts, participants initially returned a mailed questionnaire detailing their medical history as well as lifestyle and behavioral risk factors for chronic disease. Follow-up questionnaires were subsequently sent every 2 years, and follow-up rates consistently exceed 90% of available person-years. (25) In this study, we defined baseline as 1980 (NHS) and 1986 (HPFS), when specific behavioral data, including alcohol consumption and aspirin medication use, were first ascertained. Deaths in either cohort were identified through reports from family members in response to follow-up questionnaires, and from the National Death Index. We excluded individuals with any diagnosis of cancer at baseline (excepting nonmelanoma skin cancer), and those with missing information on diabetes status or a missing date of diagnosis for either diabetes or HCC. Both the NHS and HPFS studies were approved by the Institutional Review Board of the Brigham and Women's Hospital and Harvard T.H. Chan School of Public Health (Boston, MA).
ASSESSMENT OF T2D
On the baseline and subsequent biennial questionnaires, participants were asked if and on what date they had been diagnosed with diabetes by a physician. Self-reported diabetes resulted in a subsequent mailing requesting additional information regarding diagnosis date, diagnostic testing, and symptoms. Beginning in 1986 in both cohorts, questionnaires were updated to query the regular use of insulin or oral hypoglycemic medications. T2D diagnosed before 1988 was defined according to the National Diabetes Data Group criteria (26) and using the American Diabetes Association criteria for cases identified after 1998. (27) Duration of diabetes was calculated by subtracting the date of diagnosis from the date of the most recent completed questionnaire. The validity of the supplementary questionnaire for T2D diagnosis has been confirmed by medical record review in past studies in the NHS and HPFS, with positive predictive value exceeding 97%. (28, 29) 
ASSESSMENT OF HCC
In both the NHS and HPFS, self-reported diagnoses of liver cancer were obtained from biennial questionnaires, and all participants reporting liver cancer were asked for permission to acquire and review their medical records, relevant imaging, and histopathology. A study physician, blinded to exposure information, reviewed all records to confirm HCC diagnoses and extracted information from the medical charts regarding anatomic features, presence of underlying cirrhosis diagnosed by histopathology or by appropriate crosssectional imaging, and presence of documented viral hepatitis. Subjects whose diagnoses of HCC could not be confirmed (n 5 5) were excluded from analyses. A total of 112 confirmed HCC cases were documented between 1980 and 2012, including 43 cases in men and 69 cases in women. Of these, 47 cases arose in individuals without underlying cirrhosis. We also documented 31 cases of intrahepatic cholangiocarcinoma (ICC).
ASSESSMENT OF COVARIATES
Information on age, height, weight, smoking status, alcohol intake, and personal and family medical history was collected at baseline and on each biennial questionnaire. Body mass index (BMI) was computed from each questionnaire using weight in kilograms divided by height in square meters. Self-reported body weight in both cohorts has previously been highly correlated with technician-measured weights (r 5 0.96). (30) Leisure-time physical activity, expressed as the average number of metabolic equivalents (METs) expended per week, was first assessed in 1986. Information on physician-diagnosed hypercholesterolemia was collected at the cohort baseline and updated on each biennial questionnaire. A validation study from a random subset of NHS and HPFS participants demonstrated that self-reported cholesterol was correlated with serum cholesterol levels (Spearman correlation coefficients of 0.56 in NHS and 0.51 in HPFS). (23, 31) 
STATISTICAL ANALYSIS
Participants were followed prospectively for the diagnosis of HCC from 1980 (NHS) or 1986 (HPFS) through 2012. Person-time for each participant was calculated from the date of return for the initial questionnaire until date of death, HCC diagnosis, last questionnaire returned, or the end of study follow-up (January 31, 2012 in HPFS; June 1, 2012 in NHS), whichever came first. Status of confirmed T2D was ascertained and updated biennially and modeled as a time-dependent variable, to account for any incident diagnosis of diabetes over study follow-up.
To evaluate the association between T2D and HCC risk, we used Cox proportional hazards modeling to calculate age-and multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs). The following covariates were included: age in years, sex, race, family history of diabetes, smoking status (current, former, or never), BMI (kg/m 2 ), alcohol intake (g/day), physical activity (METs/week), regular aspirin use (2 aspirin tablets per week), and physician-diagnosed dyslipidemia and hypertension. The proportionality assumption was not violated. We observed no heterogeneity in the association of diabetes with HCC in separate analyses of NHS and HPFS (P heterogeneity 5 0.14); therefore, individual-level data were pooled, and we adjusted for cohort in all analyses.
In stratified analyses, we tested for effect modification by putative HCC risk factors, including age, sex, BMI, history of hypertension, history of dyslipidemia, smoking status, alcohol consumption, and use of regular aspirin. We tested the significance of interaction using the log likelihood ratio test, comparing the model that included cross-classified categories to a model that included these factors as independent variables.
To determine whether metabolic comorbidities are associated with overall HCC risk, we grouped each participant into one of five categories according to number of comorbid metabolic conditions, which included obesity (BMI 30kg/m 2 ), hypertension, dyslipidemia, and T2D. We tested for linear trend by including the number of comorbidities as a continuous term in the final model. We also conducted an exploratory analysis of antidiabetic medications and HCC risk in those with T2D, using 1986 as baseline.
A series of four sensitivity analyses were conducted. First, we excluded any individual diagnosed with HCC within 4 years of a diagnosis of T2D (n 5 4). Second, we excluded any individual with HCC found to be associated with either hepatitis B virus (HBV) or hepatitis C virus (HCV; n 5 21). Third, we tested whether the association between T2D and liver cancer risk is specific to HCC, by assessing the relationship between T2D and the second-most common histological type of primary liver cancer, ICC (n 5 33). Fourth, to test the relationship between diabetes and risk of noncirrhotic HCC, we excluded any individuals with confirmed cirrhosis (n 5 23) or unknown cirrhosis status (n 5 41) at the time of HCC diagnosis.
All P values were two-tailed, and P < 0.05 was considered statistically significant. All statistical analyses were performed using SAS software (version 9.4; SAS Institute Inc., Cary, NC).
Results
Among 120,826 women in the NHS and 50,284 men in the HPFS, we documented 112 incident cases of HCC (69 women, 43 men) over 4,488,410 total person-years of follow-up. Table 1 presents the ageadjusted characteristics of the study population by T2D status, in 1996; the midpoint of follow-up was selected to provide the best representation of characteristics during the follow-up period. Compared to nondiabetics, participants with T2D were more likely to have obesity (39.2% vs. 14.6%), hypertension (57.4% vs. 26.1%), dyslipidemia (51.3% vs. 27.8%), and a family history of diabetes (46.7% vs. 22.8%). . In stratified analyses, the positive associations between T2D and HCC were consistent across all prespecified strata (all P interactions >0.05; Table 3 ).
DIABETES DURATION AND HCC RISK
The magnitude of HCC risk increased significantly with increasing duration of T2D (P trend <0.0001; Table 4 ). Compared to nondiabetics, the multivariable-adjusted HR for HCC was 2.96 (95% CI, 1.57-5.60) for 0-<2 years of T2D; HR 6.08 (95% CI, 2.96-12.5) for 2-<10 years of T2D; and HR 7.52 (95% CI, 3.88-14.6) for 10 years of T2D (Table 3) . Table S1 ).
We also tested the hypothesis that among diabetics, antidiabetic medications might impact HCC risk (Supporting Table S2 
ANALYSIS OF METABOLIC COMORBIDITIES
An increasing number of metabolic comorbidities (T2D, obesity [BMI 30kg/m 2 ], hypertension, and dyslipidemia) was associated with a statistically significant, dose-dependent increase in HCC risk (P trend <0.0001; Fig. 1 (Fig. 1 ).
Exploratory and Sensitivity Analyses
In the first sensitivity analysis, we excluded any case of HCC occurring within 4 years of a T2D diagnosis (n 5 4 excluded) to minimize reverse causation or detection bias, and our results were similar (adjusted HR, 3 
Discussion
In two large, prospective cohorts of U.S. men and women, with over 26 years of follow-up, we observed a statistically significant association between the diagnosis of T2D and increased risk for incident HCC. This risk was significantly enhanced in individuals with a prolonged duration of diabetes and in those with an increasing number of comorbid metabolic conditions. Moreover, the association between diabetes and increased HCC risk remained significant even in those without underlying cirrhosis. ), as a time-dependent covariate. ‡ Model 3 adjusted Model 2 1 alcohol intake (0.0-4.9, 5.0-14.9, or 15 g/day), smoking status (current vs. prior vs. never), physical activity (<3, 3.0-8.9, or 9 MET-hours/week), regular aspirin use (non-use vs. use of at least 2 aspirin tablets per week), and family history of diabetes (no vs. yes). All covariates are updated over time.
§ P trend calculated by including duration of diabetes (months, continuous) in the relevant multivariable-adjusted model. Abbreviation: PY, person-years.
These findings are supported by a growing body of literature demonstrating that T2D is an important HCC risk factor, (11, 14) including a recent pooled analysis in which T2D was associated with a 2.6-fold increased risk of primary liver cancer. (15) Our study extends these data in several important ways. First, we confirmed all cases of HCC, without reliance upon administrative billing codes that may not accurately distinguish HCC from other liver neoplasms, or identify cases of noncirrhotic HCC. Second, this represents a large, prospective cohort of men and women that comprehensively accounts for multiple factors that influence the relationship between T2D and HCC, including diabetes duration, antidiabetic medications, and metabolic comorbidities. Finally, by using prospectively ascertained and serially updated covariate information, this analysis minimizes exposure misclassification, thus providing a more precise estimation of the magnitude of HCC risk in this population.
Several biological mechanisms have been proposed to explain the link between T2D and HCC. T2D may promote tumorigenesis through stimulation of IGF-1 signaling, given that prolonged insulin resistance and hyperinsulinemia reduce concentrations of IGF-binding proteins and increase bioavailable IGF-1 and IGF-II, which stimulate cellular proliferation and inhibit apoptosis. (7) IGF overexpression has been shown to promote hepatocarcinogenesis (HCG) through activation of Wnt signaling through a phosphoinositide 3-kinase/ ß-catenin-mediated pathway, (32) and IGF-II/IGF-1 receptor signaling may also enhance self-renewal of hepatic cancer stem cells. (33) Additionally, hyperglycemia may further contribute to HCG, given that accelerated glucose metabolism is a hallmark of many malignancies, including HCC, (34) and a recent multinational cohort study found that chronic hyperglycemia related to prolonged type 1 diabetes was similarly associated with increased risk of primary liver cancer. (35) Finally, it has been shown that in the setting of NAFLD, comorbid diabetes promotes intrahepatic lipid peroxidation and reactive oxygen species formation, which can accelerate DNA damage and culminate in the development of HCC. (3, 6, 17) In this population, we observed a parallel increase in risk for HCC with increasing metabolic comorbidities, supporting a central role for IR in the pathogenesis of HCC. Each of the comorbidities assessed-obesity, T2D, hyperlipidemia, and hypertension-reflect components of MetS, linked through a shared association with overnutrition and IR. (36) Although the association between obesity and HCC risk is well established, (15) less is known about the potential contributions of hypertension or dyslipidemia to the magnitude of that risk, and the limited available data are conflicting. (17, (37) (38) (39) In one prospective Taiwanese cohort, hypertension was associated with increased HCC-related mortality (HR, 2.03 [95% CI, 1.53-2.70]), (40) and in two recent analyses of U.S. insurance claims data, positive associations were found between hypertension, dyslipidemia, and risk for HCC. (17, 41) The present study confirms these observations and further demonstrates in a well-characterized, prospective cohort that increasing metabolic dysfunction is associated with a dose-dependent increase in HCC risk.
In the setting of diabetes or obesity, the pathogenesis of HCC is likely mediated through the progression of NAFLD. Up to 90% of individuals who are diabetic or obese have significant intrahepatic fat accumulation, (42) and in longitudinal NAFLD cohorts with paired liver biopsies, the presence of diabetes increases fibrosis progression, whereas improved glycemic control correlates with fibrosis regression. (43) Although HCC is heavily influenced by the presence of , dyslipidemia, hypertension and type 2 diabetes. u P-trend calculated by including the number of increasing comorbidities as a continuous term, in the fully-adjusted multivariable model. *Multivariable model adjusted for age (years, continuous), sex, race (white vs. non-white), smoking status (past, current, never), family history of diabetes, alcohol consumption (0 2 4.9 g/day, 5-14.9 g/day, 15 g/day), physical activity level (metabolic equivalent-hours/week) and regular aspirin use (defined as regular use of 2 tablets of aspirin/ week), with all relevant variables updated over time.
underlying cirrhosis, accumulating evidence now shows that nearly 40% of NAFLD-associated HCCs arise in noncirrhotic livers, particularly in those with evidence of MetS. (44, 45) To date, however, these data are derived primarily from retrospective studies (44, 46, 47) or from administrative data sets lacking individual patient information or adjudicated outcomes. (17, 48, 49) This represents a prospective analysis utilizing serially updated exposure information to demonstrate an association between T2D and increased risk for HCC, regardless of underlying cirrhosis status. These data thereby support work suggesting that the at-risk population for HCC may be far larger than estimated and highlight the need for future studies to define appropriate strategies for HCC risk stratification and early detection in individuals with and without cirrhosis.
Data are limited regarding the relationship between T2D duration and HCC risk. Most published reports only assess T2D status at one point in time, (5, (18) (19) (20) (21) (22) an approach that does not capture incident cases arising during study follow-up and may lead to the attenuation of longitudinal risk estimates. This is particularly relevant when considering the natural history of T2D, which is marked by protracted IR and compensatory hyperinsulinemia that can precede a formal diagnosis by several years. (36) The present study benefitted from prospectively ascertained and updated data, which provide evidence for an association between an increasing duration of T2D and increased risk of developing HCC.
A body of evidence now suggests that in T2D, antidiabetic medication use may impact HCC risk. In a recent meta-analysis, metformin was associated with a 50% reduction in HCC risk, whereas insulin was associated with a 161% increase in risk. (50) This was confirmed in a comparative network meta-analysis of antidiabetic treatments, in which metformin was superior to insulin for HCC risk reduction (relative risk, 0.30; 95% CI, 0.18-0.50).
(51) Although we did not find an association between oral antidiabetics and HCC risk reduction, our cohorts lacked information regarding individual oral antidiabetic agents. It is possible that the combination of metformin with oral insulin secretagogues-which likely have opposing effects on HCC risk-resulted in a null association. Given this, we eagerly await future prospective studies with detailed data on individual hypoglycemic agents.
Strengths of this study include a prospective design and a large, well-characterized population, with detailed information on clinical risk factors for HCC, and carefully adjudicated clinical endpoints. (28) However, several limitations should be considered. First, participants in these cohorts are predominantly white health care professionals. However, our age-specific incidence of HCC approximates published rates from other U.S. populations (15) and previous studies have demonstrated that the anthropormophic and lifestyle covariates in these cohorts are comparable to the broader population. (23, 24) Second, this study may be subject to detection bias, if individuals with diabetes are more likely to receive medical attention and come under enhanced surveillance for symptoms suggestive of HCC. However, this seems unlikely given that the exclusion of HCC cases arising within 4 years of a T2D diagnosis did not materially impact our results. Third, despite careful adjustment for lifestyle and clinical factors, these cohorts lack information regarding severity of underlying diabetes, thus raising the possibility of confounding by indication. Fourth, we cannot exclude the possibility of residual confounding, particularly because we were unable to ascertain the status of underlying chronic liver disease within the study population. Despite this, the ageand multivariable-adjusted analyses provided similar results, which were not altered after exclusion of individuals with either viral hepatitis-associated HCC or cirrhotic HCC. Finally, we acknowledge that the number of outcomes in certain subgroups is small; however, we note that these numbers are similar to other published prospective, epidemiological studies of HCC.
In conclusion, this study confirms that T2D is an independent risk factor for HCC, and demonstrates, in a U.S. population of men and women that the presence of metabolic comorbidities enhances the magnitude of HCC risk, in a dose-dependent fashion. These findings suggest that IR and MetS play a central role in the pathogenesis of HCC.
